A combination of flk1-based DNA vaccine and an immunomodulatory gene (IL-12) in the treatment of murine cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 19, Issue 5, 2004, Pages 649-657

  Keke, Feng ^a   Hongyang, Zhao ^a   Hui, Qiu ^b   Jixiao, Liu ^a   Jian, Chen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Attenuated Salmonella typhimurium; Flk1; Interleukin 12; Synergy

Indexed keywords

CHROMIUM 51; DNA VACCINE; IMMUNOMODULATING AGENT; PLASMID DNA; RECOMBINANT INTERLEUKIN 12; SALMONELLOSIS VACCINE; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ATTENUATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE MODEL; DNA VECTOR; GENE THERAPY; GLIOBLASTOMA; GROWTH INHIBITION; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; VASCULARIZATION;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD31; APOPTOSIS; CANCER VACCINES; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DNA; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INTERLEUKIN-12; MICE; MICE, INBRED C57BL; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PLASMIDS; PROLIFERATING CELL NUCLEAR ANTIGEN; SALMONELLA TYPHIMURIUM; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 9144241382     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/1084978042484795     Document Type: Article

References (26)

1. Plate KH, Breier G, Risau W. Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol 1994;4:207.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353.
3. Folkman J. Can mosaic tumor vessels facilitate molecular diagnosis of cancer? Proc. Natl Acad Sci USA 2001;98:398.
4. Wei YQ, Wang QR, Zhao X, et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000;6:1160.
5. Li Y, Wang MN, Li H, et al. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med 2002;1195:1575.
6. Niethammer AG, Xiang R, Becker JC, et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 2002;8:1369.
7. Storkus W, Tahara H, Lotze MT. Interleukin-12. Thomson, AW ed. The cytokine handbook 391. New York: Academic Press, 1998.
8. Bramson JL, Hitt M, Addison CL, et al. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther 1996;20:1995.
9. Coughlin CM, Salhany KE, Gee MS, et al. Tumor cell responses to IFN-7 affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 1998;9:34.
10. Bramson J, Hitt M, Gallichan WS, et al. Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: In vitro and in vivo production of biologically active interleukin-12. Hum Gene Ther 1996;7:333.
11. Coughlin CM, Salhany KE, Wysocka M, et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 1998;101:1441.
12. Angiolollo AL, Sgadari C, Taub DD, et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995;182:162.
13. Marshall E. Cancer trial of interleukin-12 halted. Science 1995;268:1555.
14. Car BD, Eng VM, Lipman JM, et al. The toxicology of interleukin-12: A review. Toxicol Pathol 1999;27:58.
15. Colombo MP, Vagliani M, Spreafico F, et al. Amount of interleukin-12 available at the tumor site is critical for tumor regression. Cancer Res 1996;56:2531.
16. Rakhmilevich AL, Timmins JG, Janssen K, et al. Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: A direct comparison with systemic IL-12 protein therapy. J Immunother 1999;22:135.
17. Matthews W, Jordan CT, Gavin M, et al. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc Natl Acad Sci USA 1991;88:9026.
18. Garlanda C, Parravicini C, Sironi M, et al. Progressive growth in immunodeficient mice and host-cell recruitment by mouse endothelial cells transformed by polyoma middle-sized T antigen: Implications for the pathogenesis of opportunistic vascular tumors. Proc Natl Acad Sci USA 1994;91:7291.
19. Huebener N, Lange B, Lemmel C, et al. Vaccination with minigenes encoding for novel "self" antigens are effective in DNA-vaccination against neuroblastoma. [letter] Cancer 2003;197:211.
20. Addison C, Bramson JL, Hitt M, et al. Intratumoral coinjection of adenoviral vectors expressing IL-12 and IL-12 results in enhanced frequency of regression of injected and untreated tumors. Gene Ther 1998;5:1400.
21. Gately MK, Warrier RR, Honasoge S, et al. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-7 in vivo. Int Immunol 1994;6:157.
22. Ochsenbein AF, Sierro S, Odermatt B. Roles of tumour localization, second signals, and cross-priming in cytotoxic T-cell induction. Nature 2001;411:1058.
23. Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999;13:1055.
24. Shi F, Rakhmilevich AL, Heise CP. Intratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine model. Mol Cancer Ther 2002;1:949.
25. Weber SM, Shi F, Heise C, et al. Interleukin-12 gene transfer results in CD8-dependent regression of murine CT26 liver tumors. Ann Surg Oncol 1999;6:186.
26. van Herpen CM, Looman M, Zonneveld M, et al. Intratumoral administration of recombinant human interleukin-12 in head and neck squamous-cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes. Clin Cancer Res 2004;10:2626.